<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EGRIFTA - tesamorelin 
			 </strong><br>EMD Serono, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use EGRIFTA® safely and effectively. See full prescribing information for EGRIFTA®.<br><br>EGRIFTA® (tesamorelin for injection), for subcutaneous use<br>Initial U.S. Approval: 2010</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="top" width="80%">
<col align="right" valign="top" width="20%">
<tbody class="Headless">
<tr>
<td align="left">Dosage and Administration, Reconstitution Procedure (<a href="#s2.2">2.2</a>)</td>
<td align="right">11/2011</td>
</tr>
<tr>
<td align="left">Dosage and Administration, Administration (<a href="#s2.3">2.3</a>)</td>
<td align="right">11/2011</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">EGRIFTA<span class="Italics">®</span> is a growth hormone releasing factor (GRF) analog indicated for the reduction of excess abdominal fat in HIV-infected patients with <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>: (<a href="#s1">1</a>) </p>
<p class="Highlighta">Limitations of use: </p>
<ul class="Disc">
<li> Long-term cardiovascular benefit and safety of EGRIFTA<span class="Italics">®</span> have not been studied. (<a href="#s1">1</a>)</li>
<li> Not indicated for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> management (weight neutral effect). (<a href="#s1">1</a>)</li>
<li> There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA<span class="Italics">®</span>. (<a href="#s1">1</a>)</li>
</ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li> Recommended dose of EGRIFTA<span class="Italics">®</span> is 2 mg injected subcutaneously once daily<span class="Bold">.</span> (<a href="#s2.1">2.1</a>)</li>
<li>Reconstitute with diluent provided as recommended. (<a href="#s2.2">2.2</a>)</li>
<li>Administer subcutaneously into abdominal skin, rotating sites. (<a href="#s2.3">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Each vial of EGRIFTA<span class="Italics">®</span> contains 2 mg of tesamorelin (<a href="#s3">3</a>). Another vial contains the reconstitution diluent, Sterile Water for Injection, USP<span class="Bold">.</span> (<a href="#s3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li> Disruption of the hypothalamic-pituitary axis due to hypophysectomy, <span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">hypopituitarism</span> or pituitary tumor/surgery, head irradiation or head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> (<a href="#s4.1">4.1</a>)</li>
<li> Active malignancy (<a href="#s4.2">4.2</a>)</li>
<li> Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to tesamorelin and/or mannitol (<a href="#s4.3">4.3</a>)</li>
<li> Pregnancy (<a href="#s4.4">4.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li> Neoplasms: Preexisting malignancy should be inactive and its treatment complete prior to starting EGRIFTA<span class="Italics">®</span> therapy<span class="Bold">.</span> (<a href="#s5.1">5.1</a>)</li>
<li> Elevated IGF-1: Monitor regularly in all patients. Consider discontinuation in patients with persistent elevations. (<a href="#s5.2">5.2</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>: May include <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span>. (<a href="#s5.3">5.3</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">Glucose intolerance</span>: May develop with EGRIFTA<span class="Italics">®</span> use. Evaluate glucose status prior to and during therapy with EGRIFTA<span class="Italics">®</span>. (<a href="#s5.4">5.4</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>): Advise patients to seek immediate medical attention if suspected. (<a href="#s5.5">5.5</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span>: Advise patients to rotate sites. (<a href="#s5.6">5.6</a>)</li>
<li> Acute critical illness: Consider discontinuation<span class="Bold">.</span> (<a href="#s5.7">5.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most commonly reported adverse reactions (&gt;5% and more frequent than placebo): <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, injection site pruritis, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>. (<a href="#s6.1">6.1</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact EMD Serono at 1-800-283-8088 ext. 5563 or FDA at 1-800-FDA-1088 or </span><span class="Bold Italics">www.fda.gov/medwatch</span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>Cytochrome P450-metabolized drugs: Monitor carefully if used with EGRIFTA<span class="Italics">®.</span> (<a href="#s7.1">7.1</a>)</li></ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li> Nursing mothers: HIV-1 infected mothers should not human milk-feed to avoid potential postnatal transmission of HIV-1. (<a href="#s8.3">8.3</a>)</li>
<li> Pediatric use: Safety and efficacy not established. (<a href="#s8.4">8.4</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION, FDA-approved patient labeling, and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 3/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 	General Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 	Reconstitution Procedure </a></h2>
<h2><a href="#section-2.3" class="toc">2.3 	Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 	Disruption of the Hypothalamic-pituitary Axis </a></h2>
<h2><a href="#section-4.2" class="toc">4.2 	Active Malignancy </a></h2>
<h2><a href="#section-4.3" class="toc">4.3		<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> </a></h2>
<h2><a href="#section-4.4" class="toc">4.4		Pregnancy</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 	Neoplasms </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 	Elevated IGF-1</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 	<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 	<span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">Glucose Intolerance</span> </a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reactions</span> </a></h2>
<h2><a href="#section-5.7" class="toc">5.7		Acute Critical Illness </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 	Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2		Immunogenicity</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1		Cytochrome P450-Metabolized Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2     11β-Hydroxysteroid Dehydrogenase Type 1 (11βHSD-1)</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6		Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">EGRIFTA<span class="Italics">®</span> (tesamorelin for injection) is indicated for the reduction of excess abdominal fat in HIV-infected patients with <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> <span class="Italics">[see <a href="#s14">Clinical Studies (14)</a>].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<p class="First">Limitations of Use:</p>
<ul class="Disc">
<li>Since the long-term cardiovascular safety and potential long-term cardiovascular benefit of EGRIFTA<span class="Italics">®</span> treatment have not been studied and are not known, careful consideration should be given whether to continue EGRIFTA<span class="Italics">®</span> treatment in  patients who do not show a clear efficacy response as judged by the degree of reduction in visceral adipose tissue measured by waist circumference or CT scan.</li>
<li>EGRIFTA<span class="Italics">®</span> is not indicated for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> management (weight neutral effect).</li>
<li>There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA<span class="Italics">®.</span>
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 	General Dosing Information</h2>
<p class="First">The recommended dose of EGRIFTA<span class="Italics">® </span>is 2 mg injected subcutaneously once a day.</p>
<p>The recommended injection site is the abdomen. Injection sites should be rotated to different areas of the abdomen. Do not inject into <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scar</span> tissue, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruises</span> or the navel.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 	Reconstitution Procedure </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">EGRIFTA® must be reconstituted with the diluent provided with the product.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Reconstitute the 2 mg vial of EGRIFTA® with 2.1 mL of diluent. Mix by rolling the vial gently in your hands for 30 seconds. <span class="Bold">Do not shake.</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Detailed instructions for reconstituting EGRIFTA® are provided in the INSTRUCTIONS FOR USE leaflet enclosed in the boxes containing EGRIFTA® and diluent.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Administer EGRIFTA® immediately following reconstitution and throw away any unused EGRIFTA® solution. If not used immediately, the reconstituted EGRIFTA<span class="Italics">®</span> solution should be discarded. Do not freeze or refrigerate the reconstituted EGRIFTA<span class="Italics">®</span> solution.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 	Administration</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Reconstituted EGRIFTA<span class="Italics">®</span> solution should always be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. EGRIFTA<span class="Italics">®</span> must be injected only if the solution is clear, colorless and without particulate matter.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">EGRIFTA® should be injected subcutaneously into the skin on the abdomen. Injection sites should be rotated to different areas of the abdomen. Do not inject into <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scar</span> tissue, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruises</span> or the navel.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">EGRIFTA<span class="Italics">®</span> (tesamorelin for injection) is supplied in a vial containing 2 mg of tesamorelin as a lyophilized powder. The diluent (Sterile Water for Injection, USP 10 mL) is provided in a separate bottle.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1 	Disruption of the Hypothalamic-pituitary Axis </h2>
<p class="First">EGRIFTA<span class="Italics">®</span> is contraindicated in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, <span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">hypopituitarism</span>, pituitary tumor/surgery, head irradiation or head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2 	Active Malignancy </h2>
<p class="First">EGRIFTA<span class="Italics">®</span> is contraindicated in patients with active malignancy (either newly diagnosed or recurrent). Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with EGRIFTA<span class="Italics">®</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4.3"></a><a name="section-4.3"></a><p></p>
<h2>4.3		<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> </h2>
<p class="First">EGRIFTA<span class="Italics">®</span> is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to tesamorelin and/or mannitol (an excipient) <span class="Italics">[see <a href="#s5.5">Warnings and Precautions (5.5)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s4.4"></a><a name="section-4.4"></a><p></p>
<h2>4.4		Pregnancy</h2>
<p class="First">EGRIFTA® is contraindicated in pregnant women. During pregnancy, visceral adipose tissue increases due to normal metabolic and hormonal changes. Modifying this physiologic change of pregnancy with EGRIFTA® offers no known benefit and could result in fetal harm. Tesamorelin acetate administration to rats during organogenesis and lactation resulted in <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephalus</span> in offspring at a dose approximately two and four times the clinical dose, respectively, based on measured drug exposure (AUC). If pregnancy occurs, discontinue EGRIFTA® therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus <span class="Italics">[see <a href="#s8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 	Neoplasms </h2>
<p class="First">EGRIFTA<span class="Italics">®</span> induces the release of endogenous growth hormone (GH), a known growth factor. Thus, patients with active malignancy should not be treated with EGRIFTA<span class="Italics">® </span><span class="Italics">[see <a href="#s4.2">Contraindications (4.2)</a>]</span>.</p>
<p>For patients with a history of non-malignant neoplasms, EGRIFTA<span class="Italics">®</span> therapy should be initiated after careful evaluation of the potential benefit of treatment. For patients with a history of treated and stable malignancies, EGRIFTA<span class="Italics">®</span> therapy should be initiated only after careful evaluation of the potential benefit of treatment relative to the risk of re-activation of the underlying malignancy.</p>
<p>In addition, the decision to start treatment with EGRIFTA<span class="Italics">®</span> should be considered carefully based on the increased background risk of malignancies in HIV-positive patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 	Elevated IGF-1</h2>
<p class="First">EGRIFTA<span class="Italics">®</span> stimulates GH production and increases serum IGF-1. Given that IGF-1 is a growth factor and the effect of prolonged elevations in IGF-1 levels on the development or progression of malignancies is unknown, IGF-1 levels should be monitored closely during EGRIFTA® therapy. Careful consideration should be given to discontinuing EGRIFTA® in patients with persistent elevations of IGF-1 levels (e.g., &gt;3 SDS), particularly if the efficacy response is not robust (e.g., based on visceral adipose tissue changes measured by waist circumference or CT scan).</p>
<p>During the clinical trials, patients were monitored every three months. Among patients who received EGRIFTA<span class="Italics">®</span> for 26 weeks, 47.4% had IGF-1 levels greater than 2 standard deviation scores (SDS), and 35.6% had SDS &gt;3, with this effect seen as early as 13 weeks of treatment. Among those patients who remained on EGRIFTA<span class="Italics">®</span> for a total of 52 weeks, at the end of treatment 33.7% had IGF-1 SDS &gt;2 and 22.6% had IGF-1 SDS &gt;3.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 	<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> may occur during EGRIFTA<span class="Italics">®</span> therapy and is thought to be related to the induction of GH secretion. It manifests as increased tissue turgor and musculoskeletal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> resulting in a variety of adverse reactions (e.g. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span>) which are either transient or resolve with discontinuation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 	<span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">Glucose Intolerance</span> </h2>
<p class="First">EGRIFTA<span class="Italics">®</span> treatment may result in <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>. During the Phase 3 clinical trials, the percentages of patients with elevated HbA<span class="Sub">1c</span> (≥ 6.5%) from baseline to Week 26 were 4.5% and 1.3% in the EGRIFTA<span class="Italics">®</span> and placebo groups, respectively. An increased risk of developing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with EGRIFTA<span class="Italics">®</span>  (HbA<span class="Sub">1c</span> level ≥ 6.5%) relative to placebo was observed [intent-to-treat hazard odds ratio of 3.3 (CI 1.4, 9.6)]. Therefore, glucose status should be carefully evaluated prior to initiating EGRIFTA<span class="Italics">®</span> treatment. In addition, all patients treated with EGRIFTA<span class="Italics">®</span> should be monitored periodically for changes in glucose metabolism to diagnose those who develop impaired glucose tolerance or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> is a known cardiovascular risk factor and patients who develop <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> have an elevated risk for developing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Caution should be exercised in treating HIV-positive patients with <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> with EGRIFTA<span class="Italics">®</span> if they develop <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and careful consideration should be given to discontinuing EGRIFTA<span class="Italics">®</span> treatment in patients who do not show a clear efficacy response as judged by the degree of reduction in visceral adipose tissue by waist circumference or CT scan measurements.</p>
<p>Since EGRIFTA<span class="Italics">®</span> increases IGF-1, patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who are receiving ongoing treatment with EGRIFTA® should be monitored at regular intervals for potential development or worsening of <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may occur in patients treated with EGRIFTA<span class="Italics">®</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> occurred in 3.6% of patients with HIV-associated <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> treated with EGRIFTA® in the Phase 3 clinical trials. These reactions included <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and other <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In cases of suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, patients should be advised to seek prompt medical attention and treatment with EGRIFTA<span class="Italics">®</span> should be discontinued immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reactions</span> </h2>
<p class="First">EGRIFTA® treatment may cause <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>, including injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, irritation, and <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>. The incidence of <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> was 24.5% in EGRIFTA®-treated patients and 14.4% in placebo-treated patients during the first 26 weeks of treatment in the Phase 3 clinical trials. For patients who continued EGRIFTA® for an additional 26 weeks, the incidence of <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> was 6.1%. In order to reduce the incidence of <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>, it is recommended to rotate the site of injection to different areas of the abdomen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7		Acute Critical Illness </h2>
<p class="First">Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or those with <span class="product-label-link" type="condition" conceptid="319049" conceptname="Acute respiratory failure">acute respiratory failure</span> has been reported after treatment with pharmacologic amounts of growth hormone. EGRIFTA<span class="Italics">®</span> has not been studied in patients with acute critical illness. Since EGRIFTA<span class="Italics">®</span> stimulates growth hormone production, careful consideration should be given to discontinuing EGRIFTA<span class="Italics">®</span> in critically ill patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The most commonly reported adverse reactions are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>) reactions due to the effect of GH (e.g., <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, extremity <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span>), <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> (injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, pruritis, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, irritation, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>).</p>
<p>During the first 26 weeks of treatment (main phase), discontinuations as a result of adverse reactions occurred in 9.6% of patients receiving EGRIFTA<span class="Italics">®</span> and 6.8% of patients receiving placebo. Apart from patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> identified during the studies and who were discontinued per protocol (2.2%), the most common reasons for discontinuation of EGRIFTA® treatment were adverse reactions due to the effect of GH (4.2%) and local <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> (4.6%).</p>
<p>During the following 26 weeks of treatment (extension phase), discontinuations as a result of adverse events occurred in 2.4% of patients in the T-T group (patients treated with tesamorelin for Week 0-26 and with tesamorelin for Week 26-52) and 5.2% of patients in the T-P group (patients treated with tesamorelin for Week 0-26 and with placebo for Week 26-52).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 	Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Seven hundred and forty HIV-infected patients with <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> and excess abdominal fat were exposed to EGRIFTA<span class="Italics">®</span> in the Phase 3 clinical trials; of these 543 received EGRIFTA<span class="Italics">®</span> during the initial 26-week placebo-controlled phase <span class="Italics">[see <a href="#s14">Clinical Studies (14)</a>].</span></p>
<p>Adverse reactions that occurred more frequently with EGRIFTA<span class="Italics">®</span> relative to placebo and had an incidence ≥1% during the first 26 weeks across all studies are presented in Table 1.</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1. Adverse Reactions Reported in ≥ 1% and More Frequent in EGRIFTA® –treated than Placebo Patients during the 26-Week Main Phase (Combined Studies)</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Incidence of patients (%) with adverse  drug reactions</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">System Organ Class<br>Preferred Term</th>
<th class="Rrule" align="center">EGRIFTA<span class="Italics">®</span><br>(N=543)</th>
<th class="Rrule" align="center">Placebo<br>(N=263)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">13.3</td>
<td class="Rrule" align="center">11.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Rrule" align="center">6.1</td>
<td class="Rrule" align="center">4.6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">5.5</td>
<td class="Rrule" align="center">1.9</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">Musculoskeletal stiffness</span></td>
<td class="Rrule" align="center">1.7</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="72404" conceptname="Joint stiffness">Joint stiffness</span></td>
<td class="Rrule" align="center">1.5</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">Joint swelling</span></td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center">0.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">General disorders and administration site conditions</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></td>
<td class="Rrule" align="center">8.5</td>
<td class="Rrule" align="center">2.7</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Injection site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">7.6</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td class="Rrule" align="center">6.1</td>
<td class="Rrule" align="center">2.3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span></td>
<td class="Rrule" align="center">4.1</td>
<td class="Rrule" align="center">3.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4317272" conceptname="Injection site irritation">Injection site irritation</span></td>
<td class="Rrule" align="center">2.9</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">1.7</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4316205" conceptname="Injection site hemorrhage">Injection site hemorrhage</span></td>
<td class="Rrule" align="center">1.7</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4318392" conceptname="Injection site urticaria">Injection site urticaria</span></td>
<td class="Rrule" align="center">1.7</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4319319" conceptname="Injection site edema">Injection site swelling</span></td>
<td class="Rrule" align="center">1.5</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span></td>
<td class="Rrule" align="center">1.3</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4318391" conceptname="Injection site dermatitis">Injection site rash</span></td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center">0.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Rrule" align="center">4.8</td>
<td class="Rrule" align="center">2.3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></td>
<td class="Rrule" align="center">4.2</td>
<td class="Rrule" align="center">1.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">Carpal tunnel syndrome</span></td>
<td class="Rrule" align="center">1.5</td>
<td class="Rrule" align="center">0.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">4.4</td>
<td class="Rrule" align="center">3.8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">2.6</td>
<td class="Rrule" align="center">0.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">1.7</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Psychiatric disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Rrule" align="center">2.0</td>
<td class="Rrule" align="center">1.5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">3.7</td>
<td class="Rrule" align="center">1.5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">2.4</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night sweats</span></td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">1.3</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Muscle strain</span></td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center">0.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Investigations</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">Blood creatine phosphokinase</span> increased</td>
<td class="Rrule" align="center">1.5</td>
<td class="Rrule" align="center">0.4</td>
</tr>
</tbody>
</table>
<p>Mean levels of fasting blood glucose and fasting insulin were not significantly different between EGRIFTA<span class="Italics">®</span> -treated and placebo-treated patients after 26 weeks of treatment.</p>
<p>In the EGRIFTA® Phase 3 clinical trials, mean baseline (Week 0) HbA<span class="Sub">1c</span> was 5.26% among patients in the EGRIFTA® group and 5.28% among those in the placebo group. At Week 26, mean HbA<span class="Sub">1c</span> was higher among patients treated with EGRIFTA® compared with placebo (5.39% vs. 5.28% for the EGRIFTA® and placebo groups, respectively, mean treatment difference of 0.12%, p=0.0004).  Patients receiving EGRIFTA® had an increased risk of developing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (HbA<span class="Sub">1c</span> level ≥ 6.5%) compared with placebo (4.5% vs. 1.3%), with a hazard ratio of 3.3 (CI 1.4, 9.6).</p>
<p>Adverse reactions observed during Week 26 to 52 of the Phase 3 clinical trials which had an incidence of ≥1% and were seen more frequently with EGRIFTA® relative to placebo are presented in Table 2:</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2. Adverse Reactions Reported in ≥ 1% and More Frequent in EGRIFTA®–treated than Placebo Patients during the 26-Week Extension Phase of the Combined Studies (Week 26 to Week 52 of the studies)</span></caption>
<col align="left" valign="top" width="35%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Incidence of patients (%) with adverse  drug reactions</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">System Organ Class<br>Preferred Term</th>
<th class="Rrule" align="center">T-T<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> (Week 26-52)<br>(N=246)</th>
<th class="Rrule" align="center">T-P<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>(Week 26-52)<br>(N=135)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>T-T = tesamorelin for Week 0-26 and tesamorelin for Week 26-52</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>T-P = tesamorelin for Week 0-26 and placebo for Week 26-52</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Rrule" align="center">3.3</td>
<td class="Rrule" align="center">0.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">1.2</td>
<td class="Rrule" align="center">0.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">General disorders and administration site conditions</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Injection site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">2.0</td>
<td class="Rrule" align="center">0.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td class="Rrule" align="center">2.0</td>
<td class="Rrule" align="center">0.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></td>
<td class="Rrule" align="center">1.2</td>
<td class="Rrule" align="center">0.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Rrule" align="center">1.6</td>
<td class="Rrule" align="center">1.5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></td>
<td class="Rrule" align="center">1.6</td>
<td class="Rrule" align="center">0.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy peripheral</span></td>
<td class="Rrule" align="center">1.6</td>
<td class="Rrule" align="center">1.5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">2.0</td>
<td class="Rrule" align="center">0.7</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Psychiatric disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Rrule" align="center">1.6</td>
<td class="Rrule" align="center">0.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">1.2</td>
<td class="Rrule" align="center">0.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">1.2</td>
<td class="Rrule" align="center">0.7</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></td>
<td class="Rrule" align="center">1.2</td>
<td class="Rrule" align="center">0.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night sweats</span></td>
<td class="Rrule" align="center">1.2</td>
<td class="Rrule" align="center">0.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">1.6</td>
<td class="Rrule" align="center">1.5</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flush</span></td>
<td class="Rrule" align="center">1.2</td>
<td class="Rrule" align="center">0.7</td>
</tr>
</tbody>
</table>
<p>For patients who continued from Week 26-52, mean levels of fasting blood glucose, fasting insulin, and HbA<span class="Sub">1c</span> were not different between the T-T and T-P groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2		Immunogenicity</h2>
<p class="First">As with all therapeutic proteins and peptides, there is a potential for in vivo development of anti- EGRIFTA<span class="Italics">®</span> antibodies. In the combined Phase 3 clinical trials anti-tesamorelin IgG antibodies were detected in 49.5% of patients treated with EGRIFTA<span class="Italics">®</span> for 26 weeks and 47.4% of patients who received EGRIFTA® for 52 weeks. In the subset of patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, anti-tesamorelin IgG antibodies were detected in 85.2%. Cross-reactivity to endogenous growth hormone-releasing hormone (GHRH) was observed in approximately 60% of patients who developed anti-tesamorelin antibodies. Patients with and without anti-tesamorelin IgG antibodies had similar mean reductions in visceral adipose tissue (VAT) and IGF-1 response suggesting that the presence of antibodies did not alter the efficacy of EGRIFTA<span class="Italics">®</span>. In a group of patients who had antibodies to tesamorelin after 26 weeks of treatment (56%) and were re-assessed 6 months later, after stopping EGRIFTA® treatment, 18% were still antibody positive.</p>
<p>Neutralizing antibodies to tesamorelin and hGHRH were detected in vitro at Week 52 in 10% and 5% of EGRIFTA®-treated patients, respectively. They did not appear to have an impact on efficacy, as evidenced by comparable changes in VAT and IGF-1 level in patients with or without in vitro neutralizing antibodies.</p>
<p>The observed incidence of antibody positivity in an assay is highly dependent on several factors including assay sensitivity and specificity, methodology, sample handling, timing of sample collection, concomitant medication and underlying disease. For these reasons, comparison of the incidence of antibodies to EGRIFTA® with the incidence of antibodies to other products may be misleading.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1		Cytochrome P450-Metabolized Drugs</h2>
<p class="First">Co-administration of EGRIFTA<span class="Italics">®</span> with simvastatin, a sensitive CYP3A substrate, showed that EGRIFTA<span class="Italics">®</span> had no significant impact on the pharmacokinetics profiles of simvastatin in healthy subjects. This result suggests that EGRIFTA® may not significantly affect CYP3A activity. Other isoenzymes of CYP450 have not been evaluated with EGRIFTA<span class="Italics">®</span>. Published data, however, indicate that GH may modulate cytochrome P450 (CYP450) mediated antipyrine clearance in man. These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporine). Because tesamorelin stimulates GH production, careful monitoring is advisable when EGRIFTA<span class="Italics">®</span> is administered in combination with other drugs known to be metabolized by CYP450 liver enzymes <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2     11β-Hydroxysteroid Dehydrogenase Type 1 (11βHSD-1)</h2>
<p class="First">GH is known to inhibit 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1), a microsomal enzyme required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue.  Because tesamorelin stimulates GH production, patients receiving glucocorticoid replacement for previously diagnosed <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span> may require an increase in maintenance or stress doses following initiation of EGRIFTA®, particularly in patients treated with cortisone acetate and prednisone because conversion of these drugs to their biologically active metabolites is dependent on the activity of 11βHSD-1.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category X <span class="Italics">[see <a href="#s4.4">Contraindications (4.4)</a>]</span>.</p>
<p>EGRIFTA® is contraindicated in pregnant women. During pregnancy, visceral adipose tissue increases due to normal metabolic and hormonal changes. Modifying this physiologic change of pregnancy with EGRIFTA® offers no known benefit and could result in fetal harm. Tesamorelin acetate administration to rats during organogenesis and lactation resulted in <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span> in offspring at a dose of approximately two and four times the clinical dose, respectively, based on measured drug exposure (AUC). If pregnancy occurs, discontinue EGRIFTA® therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Tesamorelin acetate administration to rats during organogenesis and lactation produced <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span> in offspring at a dose of approximately two and four times the clinical dose, respectively, based on measured drug exposure (AUC). Actual animal dose was 1.2 mg/kg. During organogenesis, lower doses approximately 0.1 to 1 times the clinical dose caused delayed skull ossification in rats. Actual animal doses were 0.1 to 0.6 mg/kg. No adverse developmental effects occurred in rabbits using doses up to approximately 500 times the clinical dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">The Centers for Disease Control and Prevention recommend that HIV-infected mothers in the United States not human milk-feed their infants to avoid risking postnatal transmission of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span><span class="Bold">.</span> Because of both the potential for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> transmission and serious adverse reactions in nursing infants, mothers receiving EGRIFTA<span class="Italics">® </span>should be instructed not to human milk-feed.</p>
<p>It is not known whether EGRIFTA<span class="Italics">®</span> is excreted in human milk. Tesamorelin acetate administration to rats during organogenesis and lactation resulted in <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span> in offspring at a dose of approximately two and four times the clinical dose, respectively, based on measured drug exposure (AUC). Actual animal dose was 1.2 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. EGRIFTA® should not be used in children with open epiphyses, among whom excess GH and IGF-1 may result in linear growth acceleration and excessive growth.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There is no information on the use of EGRIFTA® in patients greater than 65 years of age with HIV and <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6		Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Safety, efficacy, and pharmacokinetics of EGRIFTA® in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No data are available on overdosage.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">EGRIFTA<span class="Italics">®</span> contains tesamorelin (as the acetate salt), an analog of human growth hormone-releasing factor (GRF). The peptide precursor of tesamorelin acetate is produced synthetically and is comprised of the 44 amino acid sequence of human GRF. Tesamorelin acetate is made by attaching a hexenoyl moiety, a C6 chain with a double bond at position 3, to the tyrosine residue at the N-terminal part of the molecule. The molecular formula of tesamorelin acetate is C<span class="Sub">221</span>H<span class="Sub">366</span>N<span class="Sub">72</span>O<span class="Sub">67</span>S • x C<span class="Sub">2</span>H<span class="Sub">4</span>O<span class="Sub">2</span> (x ≈ 7) and its molecular weight (free base) is 5135.9 Daltons. The structural formula of tesamorelin acetate is:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-01.jpg"></p>
<p>EGRIFTA<span class="Italics">®</span> is a sterile, white to off-white, preservative-free lyophilized powder for subcutaneous injection. After reconstitution with the supplied diluent (Sterile Water for Injection, USP), a solution of EGRIFTA<span class="Italics">®</span> is clear and colorless. Each single-use vial of EGRIFTA<span class="Italics">®</span> contains 2 mg of tesamorelin as the free base (2.2 mg tesamorelin acetate, anhydrous) and the following inactive ingredient: 100 mg mannitol, USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF <span class="Italics">[see <a href="#s12.2">Clinical Pharmacology (12.2)</a>]. </span></p>
<p>Growth Hormone-Releasing Factor (GRF), also known as growth hormone-releasing hormone (GHRH), is a hypothalamic peptide that acts on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH), which is both anabolic and lipolytic. GH exerts its effects by interacting with specific receptors on a variety of target cells, including chondrocytes, osteoblasts, myocytes, hepatocytes, and adipocytes, resulting in a host of pharmacodynamic effects. Some, but not all these effects, are primarily mediated by IGF-1 produced in the liver and in peripheral tissues.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Effects on IGF-1 and IGFBP-3 levels </span></p>
<p>Tesamorelin stimulates growth hormone secretion, and subsequently increases IGF-1 and IGFBP-3 levels <span class="Italics">[see <a href="#s14">Clinical Studies (14)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Underline">Other Pituitary Hormones</span></p>
<p>No clinically significant changes in the levels of other pituitary hormones, including thyroid-stimulating hormone (TSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH) and prolactin, were observed in subjects receiving EGRIFTA<span class="Italics">®</span> in Phase 3 clinical trials.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>The absolute bioavailability of EGRIFTA® after subcutaneous administration of a 2 mg dose was determined to be less than 4% in healthy adult subjects. Single and multiple dose pharmacokinetics of EGRIFTA<span class="Italics">®</span> have been characterized in healthy subjects and HIV-infected patients without <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> following 2 mg subcutaneous administration.</p>
<p>The mean values [coefficient of variation (CV)] of the extent of absorption (AUC) for tesamorelin were 634.6 (72.4) and 852.8 (91.9) pg<span class="Bold">.</span>h/mL in healthy subjects and HIV-infected patients, respectively, after a single subcutaneous administration of a 2 mg EGRIFTA<span class="Italics">®</span> dose. The mean (CV) peak tesamorelin concentration (C<span class="Sub">max</span>) values were 2874.6 (43.9) pg/mL in healthy subjects and 2822.3 (48.9) pg/mL in HIV-infected patients. The median peak plasma tesamorelin concentration (T<span class="Sub">max</span>) was 0.15 h in both populations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution </span></p>
<p>The mean volume of distribution (±SD) of tesamorelin following a single subcutaneous administration was 9.4±3.1 L/kg in healthy subjects and 10.5±6.1 L/kg in HIV-infected patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>No formal metabolism studies have been performed in humans.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Elimination</span></p>
<p>Mean elimination half-life (T<span class="Sub">1/2</span>) of tesamorelin was 26 and 38 minutes in healthy subjects and HIV-infected patients, respectively, after subcutaneous administration for 14 consecutive days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold Underline">Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Underline">Simvastatin</span></p>
<p>The effect of multiple dose administration of EGRIFTA® (2 mg) on the pharmacokinetics of simvastatin and simvastatin acid was evaluated in healthy subjects. Co-administration of EGRIFTA® and simvastatin (a sensitive CYP3A substrate) resulted in 8% decrease in extent of absorption (AUC<span class="Sub">inf</span>) and 5% increase in rate of absorption (C<span class="Sub">max</span>) of simvastatin. For simvastatin acid there was a 15% decrease in AUC<span class="Sub">inf</span> and 1% decrease in C<span class="Sub">max </span><span class="Italics">[see <a href="#s7.1">Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Underline">Ritonavir</span></p>
<p>The effect of multiple dose administration of EGRIFTA® (2 mg) on the pharmacokinetics of ritonavir was evaluated in healthy subjects. Co-administration of EGRIFTA® with ritonavir resulted in 9% decrease in AUC<span class="Sub">inf</span> and 11% decrease in C<span class="Sub">max</span> of ritonavir <span class="Italics">[see <a href="#s7">Drug Interactions</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Bold Underline">Specific Populations</span></p>
<p>Pharmacokinetics of tesamorelin in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, in pediatric patients, or in elderly patients has not been established.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Life-time carcinogenicity studies in rodents have not been conducted with tesamorelin acetate. No potential mutagenicity of tesamorelin acetate was revealed in a battery of tests including induction of gene mutations in bacteria (the Ames test), gene mutations in mammalian cells grown in vitro (hamster CHOK1 cells), and chromosomal damage in intact animals (bone marrow cells in mice). There was no effect on fertility in male or female rats following administration of tesamorelin acetate at doses up to 0.6 mg/kg (approximately equal to clinical exposure) for 28 days in males or 14 days in females. In the 26-week toxicity study in rats, females given approximately 16 and 25 times the clinical dose were more likely to be in diestrus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Two multicenter, randomized, double-blind, placebo-controlled studies were conducted in HIV-infected patients with <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> and excess abdominal fat (abdominal <span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">lipohypertrophy</span>). Both studies (Study 1 and 2) consisted of a 26-week Main Phase and a 26-week Extension Phase. Main inclusion criteria were age 18-65 years,  a waist circumference ≥95 cm (37.4 inches) and a waist-to-hip ratio ≥0.94 for men and ≥94 cm (37.0 inches) and ≥0.88 for women, respectively, and fasting blood glucose (FBG) &lt;150 mg/dL (8.33 mmol/L). Main exclusion criteria included BMI ≤ 20 kg/m<span class="Sup">2</span>, type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, if previously treated with insulin or with oral hypoglycemic or insulin-sensitizing agents, history of malignancy, and <span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">hypopituitarism</span>. Patients were on a stable anti-retroviral regimen for at least 8 weeks prior to randomization. Patients meeting the inclusion/exclusion criteria were randomized in a 2:1 ratio to receive 2 mg EGRIFTA<span class="Italics">®</span> or placebo subcutaneously daily for 26 weeks. The primary efficacy assessment for each of these studies was the percent change from baseline to Week 26 (Main Phase) in visceral adipose tissue (VAT), as assessed by computed tomography (CT) scan at L4-L5 vertebral level. Secondary endpoints included changes from baseline in patient-reported outcomes related to body image, triglycerides, ratio of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> to HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, IGF-1 levels, and safety parameters. Other endpoints included changes from baseline in waist circumference, abdominal subcutaneous tissue (SAT), trunk fat, and lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>. In both studies, EGRIFTA<span class="Italics">®</span>-treated patients completing the 26-week treatment period were re-randomized to blinded therapy with either daily placebo or 2 mg EGRIFTA<span class="Italics">®</span> for an additional 26-week treatment period (Extension Phase) in order to assess maintenance of VAT reduction and to gather long-term safety data. For inclusion in the Extension Phase studies, subjects must have completed the Main Phase with FBG ≤ 150 mg/dL.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold Underline">Main Phase (Baseline to Week 26)</span><span class="Bold">:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Italics Underline">Study 1</span></p>
<p>This study randomized 412 HIV-infected patients with <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> and excess abdominal fat to receive either EGRIFTA<span class="Italics">®</span> (N=273) or placebo (N=137). At baseline for the two groups combined, mean age was  48 years; 86% were male; 75% were white, 14% were Black/African American, and 8% were Hispanic; mean weight was 90 kg; mean BMI was 29 kg/m<span class="Sup">2</span>; mean waist circumference was 104 cm; mean hip circumference was 100 cm; mean VAT was 176 cm<span class="Sup">2</span>; mean CD4 cell count was 606 cells/mm<span class="Sup">3</span>; 69% had undetectable viral load (&lt;50 copies/mL); and 33.7% randomized to EGRIFTA<span class="Sup">®</span> and 36.6% randomized to placebo had impaired glucose tolerance, while 5.6% randomized to EGRIFTA<span class="Italics">®</span> and 6.7% randomized to placebo had diet-controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. The twenty-six week completion rate in Study 1 was 80%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Study 2</span></span></p>
<p>This study randomized 404 HIV-infected patients with <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> and excess abdominal fat to receive either EGRIFTA<span class="Italics">®</span> (N=270) or placebo (N=126). At baseline for the two groups combined, mean age was  48 years; 84% were male; 77% were white, 12% were Black/African American, and 9% were Hispanic; mean weight was 88 kg; mean BMI was 29 kg/m<span class="Sup">2</span>; mean waist circumference was 105 cm; mean hip circumference was 100 cm; mean VAT was 189 cm<span class="Sup">2</span>; mean CD4 cell count was 592 cells/mm<span class="Sup">3</span>; 83% had undetectable viral load (&lt;50 copies/mL); and 44.1% randomized to EGRIFTA<span class="Italics">®</span> and 39.7% randomized to placebo had impaired glucose tolerance, while 9.3% randomized to EGRIFTA<span class="Italics">®</span> and 9.5% randomized to placebo had diet-controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. The twenty-six week completion rate in Study 2 was 74%.</p>
<p>Results for the Main Phases of Studies 1 and 2 are presented in Tables 3 and 4.</p>
<a name="table3"></a><table width="100%">
<caption><span>Table 3: Changes from Baseline to Week 26 in Visceral Adipose Tissue (cm<span class="Sup">2</span>) by Treatment Group (Intent-To-Treat Population with Last Observation Carried Forward)</span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="5">MAIN PHASE (Baseline-Week 26)</th></tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Study 1</th>
<th class="Rrule" align="center" colspan="2">Study 2</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">EGRIFTA<span class="Italics">®</span><br>(N=273)</th>
<th class="Rrule" align="center">Placebo<br>(N=137)</th>
<th class="Rrule" align="center">EGRIFTA<span class="Italics">®</span><br>(N=270)</th>
<th class="Rrule" align="center">Placebo<br>(N=126)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5" valign="top">Baseline data are expressed as mean (SD); Change refers to least-squares mean (LSM); CI: confidence interval.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Results derived from the statistical model: Ln(VAT Week 26/VAT Baseline) = Ln(VAT Baseline) + treatment group</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Baseline (cm<span class="Sup">2</span>)</td>
<td class="Rrule" align="center">178 (77)</td>
<td class="Rrule" align="center">171 (77)</td>
<td class="Rrule" align="center">186 (87)</td>
<td class="Rrule" align="center">195 (95)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Change (cm<span class="Sup">2</span>)</td>
<td class="Rrule" align="center">-27</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">-21</td>
<td class="Rrule" align="center">-0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mean treatment difference (95% CI)</td>
<td class="Rrule" align="center" colspan="2">-31 (-39,-24)</td>
<td class="Rrule" align="center" colspan="2">-21 (-29,-12)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mean change (%)<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">-18</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">-14</td>
<td class="Rrule" align="center">-2</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Mean treatment difference (95% CI)<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center" colspan="2">-20 (-24, -15)</td>
<td class="Rrule" align="center" colspan="2">-12 (-16, -7)</td>
</tr>
</tbody>
</table>
<a name="table4"></a><table width="100%">
<caption><span>Table 4: Changes from Baseline to Week 26 in IGF-1, IGFBP-3, Weight, and Waist Circumference by Treatment Group (Intent-To-Treat Population with Last Observation Carried Forward)</span></caption>
<col align="center" valign="middle" width="15%">
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="6">MAIN PHASE (Baseline-Week 26)</th></tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Study 1</th>
<th class="Rrule" align="center" colspan="2">Study 2</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center">EGRIFTA<span class="Italics">®</span><br>(N=273)</th>
<th class="Rrule" align="center">Placebo<br>(N=137)</th>
<th class="Rrule" align="center">EGRIFTA<span class="Italics">®</span><br>(N=270)</th>
<th class="Rrule" align="center">Placebo<br>(N=126)</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="6" valign="top">Baseline data are expressed as mean (SD); Change refers to least-squares mean (LSM); CI: confidence interval.</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" rowspan="3">IGF-1<br>(ng/mL)</td>
<td class="Rrule" align="left">Baseline</td>
<td class="Rrule" align="center">161 (59)</td>
<td class="Rrule" align="center">168 (75)</td>
<td class="Rrule" align="center">146 (66)</td>
<td class="Rrule" align="center">149 (59)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Change</td>
<td class="Rrule" align="center">107</td>
<td class="Rrule" align="center">-15</td>
<td class="Rrule" align="center">108</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Mean treatment difference (95% CI)</td>
<td class="Rrule" align="center" colspan="2">122 (101, 141)</td>
<td class="Rrule" align="center" colspan="2">105 (85, 126)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" rowspan="3">IGFBP-3<br>(mg/L)</td>
<td class="Rrule" align="left">Baseline</td>
<td class="Rrule" align="center">3 (1)</td>
<td class="Rrule" align="center">3 (1)</td>
<td class="Rrule" align="center">3 (1)</td>
<td class="Rrule" align="center">3 (1)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Change</td>
<td class="Rrule" align="center">0.4</td>
<td class="Rrule" align="center">-0.2</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">-0.0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Mean treatment difference (95% CI)</td>
<td class="Rrule" align="center" colspan="2">0.6 (0.5, 0.8)</td>
<td class="Rrule" align="center" colspan="2">0.8 (0.5, 1.0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" rowspan="3">Weight (kg)</td>
<td class="Rrule" align="left">Baseline</td>
<td class="Rrule" align="center">90 (14)</td>
<td class="Rrule" align="center">90 (14)</td>
<td class="Rrule" align="center">89 (14)</td>
<td class="Rrule" align="center">87 (16)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Change</td>
<td class="Rrule" align="center">-0.4</td>
<td class="Rrule" align="center">0.0</td>
<td class="Rrule" align="center">0.5</td>
<td class="Rrule" align="center">0.3</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Mean treatment difference (95% CI)</td>
<td class="Rrule" align="center" colspan="2">-0.4 (-1.3, 0.5)</td>
<td class="Rrule" align="center" colspan="2">0.2 (-0.7, 1.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" rowspan="3">Waist circumference (cm)</td>
<td class="Rrule" align="left">Baseline</td>
<td class="Rrule" align="center">104 (10)</td>
<td class="Rrule" align="center">105 (9)</td>
<td class="Rrule" align="center">105 (9)</td>
<td class="Rrule" align="center">105 (9)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Change</td>
<td class="Rrule" align="center">-3 (5)</td>
<td class="Rrule" align="center">-1 (4)</td>
<td class="Rrule" align="center">-2 (5)</td>
<td class="Rrule" align="center">-1 (5)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">Mean treatment difference (95% CI)</td>
<td class="Rrule" align="center" colspan="2">-2 (-2.8, -0.9)</td>
<td class="Rrule" align="center" colspan="2">-1 (-2.5, -0.3)</td>
</tr>
</tbody>
</table>
<p>A subgroup analysis by gender showed that there were no statistical differences in the percent change from baseline in visceral adipose tissue (VAT) and IGF-1 responses, respectively, between males and females.</p>
<p>At Week 26, treatment with EGRIFTA<span class="Italics">®</span> resulted in a reduction from baseline in mean trunk fat of 1.0 kg in Study 1 and 0.8 kg in Study 2, respectively (compared with an increase of 0.4 kg in Study 1 and of 0.2 kg in Study 2, respectively, in patients receiving placebo). Treatment with EGRIFTA<span class="Italics">®</span> resulted in an increase from baseline in mean lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> of 1.3 kg in Study 1 and of 1.2 kg in Study 2, respectively (compared with a decrease of 0.2 kg in Study 1 and of 0.03 kg in Study 2, respectively, in patients receiving placebo).</p>
<p>On average, there were no adverse effects of EGRIFTA<span class="Italics">®</span> on lipids or subcutaneous adipose tissue (SAT). EGRIFTA<span class="Italics">®</span> did not adversely alter antiretroviral effectiveness, such as mean circulating levels of CD4 counts or HIV-1 RNA (viral load).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Underline">Patient Reported Outcomes</span></p>
<p>Patients rated the degree of distress associated with their belly appearance on a 9-point rating scale that was then transformed to a score from 0 (extremely upsetting and distressing) to 100 (extremely encouraging). A score of 50 indicated neutral (no feeling either way). A positive change from baseline score indicated improvement, i.e., less distress.</p>
<p>The cumulative distribution of response (change from baseline to 26 weeks) is shown in Figure 1 for both treatment groups. A curve shifted to the right on this scale indicates a greater percentage of patients reporting improvement.</p>
<p><span class="Bold">Figure 1. Cumulative Distribution of Response for Belly Appearance Distress</span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-02.jpg"></div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<p class="First"><span class="Bold Underline">Extension Phase (Weeks 26-52):</span></p>
<p>In the double-blind Extension Phase, patients on EGRIFTA<span class="Italics">®</span> completing the 26-week Main Phase were re-randomized to receive 2 mg EGRIFTA<span class="Italics">®</span> or placebo.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.1"></a><p></p>
<p class="First"><span class="Italics Underline">Study 1</span></p>
<p>This study re-randomized 207 HIV-infected patients with <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> who completed EGRIFTA<span class="Italics">®</span> treatment in the Main Phase to receive either EGRIFTA<span class="Italics">®</span> (N=154) or placebo (N=50) for an additional 26-week duration (3:1 randomization ratio). At baseline (Week 26) for the two groups combined, mean age was  48 years; 88% were male; 78% were white, 12% were Black/African American, and 8% were Hispanic; mean weight was 90 kg; mean BMI was 29 kg/m<span class="Sup">2</span>; mean waist circumference was 102 cm; mean hip circumference was 100 cm; mean VAT was 145 cm<span class="Sup">2</span>; mean CD4 cell count was 639 cells/mm<span class="Sup">3</span>; 68% had undetectable viral load (&lt;50 copies/mL); and for those EGRIFTA<span class="Italics">®</span>-treated patients completing the 26-week treatment period that were re-randomized to EGRIFTA<span class="Italics">®</span> (T-T group) or re-randomized to placebo, 36.6% and  32.0%, respectively, had impaired glucose tolerance, while 2.0% re-randomized to EGRIFTA<span class="Italics">®</span> and 6.0% re-randomized to placebo had diet-controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. The completion rate for patients randomized into the extension phase of Study 1 was 83%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.2"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Study 2</span></span></p>
<p>This study re-randomized 177 HIV-infected patients with <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> who completed EGRIFTA<span class="Italics">®</span> treatment in the Main Phase to receive either EGRIFTA<span class="Italics">®</span> (N=92) or placebo (N=85) for an additional 26-week duration (1:1 randomization ratio). At baseline (Week 26) for the two groups combined, mean age was 48 years; 90% were male; 84% were white, 9% were Black/African American, and 7% were Hispanic; mean weight was 89 kg; mean BMI was 28 kg/m<span class="Sup">2</span>; mean waist circumference was 105 cm; mean hip circumference was 100 cm; mean VAT was 172 cm<span class="Sup">2</span>; mean CD4 cell count was  579 cells/mm<span class="Sup">3</span>; 82% had undetectable viral load (&lt;50 copies/mL); and for those EGRIFTA<span class="Italics">®</span>-treated patients completing the 26-week treatment period that were re-randomized to EGRIFTA<span class="Italics">®</span> (T-T group) or re-randomized to placebo, 48.9% and 50.6%, respectively, had impaired glucose tolerance, while 4.3% re-randomized to EGRIFTA<span class="Italics">®</span> and 12.9% re-randomized to placebo had diet-controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. The completion rate for patients randomized into the extension phase of Study 2 was 81%.</p>
<p>Results for the Extension Phases of Studies 1 and 2 are presented in Tables 5 and 6.</p>
<a name="table5"></a><table width="100%">
<caption><span>Table 5: Changes from Week 26 Baseline to Week 52 in Visceral Adipose Tissue (cm<span class="Sup">2</span>) by Treatment Group (Intent-To-Treat Population with Last Observation Carried Forward)</span></caption>
<col align="left" valign="middle" width="24%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="19%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="5">EXTENSION PHASE (Week 26-52)</th></tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Study 1</th>
<th class="Rrule" align="center" colspan="2">Study 2</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">T-T<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a><br>(Week 26-52)<br>(N=154)</th>
<th class="Rrule" align="center">T-P<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a><br>(Week 26-52)<br>(N=50)</th>
<th class="Rrule" align="center">T-T<a href="#footnote-4" class="Sup">*</a><br>(Week 26-52)<br>(N=92)</th>
<th class="Rrule" align="center">T-P<a href="#footnote-5" class="Sup">†</a><br>(Week 26-52)<br>(N=85)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5" valign="top">Week 26 baseline data are expressed as mean (SD). Change refers to least-squares mean (LSM); CI: confidence interval.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>T-T = tesamorelin for Weeks 0-26 and tesamorelin for Weeks 26-52</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>T-P = tesamorelin for Weeks 0-26 and placebo for Weeks 26-52</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>Results derived from the statistical model: Ln(VAT Week 52/Week 26) = Ln(Week 26 VAT) + treatment group</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Week 26 (cm<span class="Sup">2</span>)</td>
<td class="Rrule" align="center">145 (72)</td>
<td class="Rrule" align="center">144 (72)</td>
<td class="Rrule" align="center">166 (89)</td>
<td class="Rrule" align="center">177 (88)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Change (cm<span class="Sup">2</span>)</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">-11</td>
<td class="Rrule" align="center">24</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mean treatment difference (95% CI)</td>
<td class="Rrule" align="center" colspan="2">-22 (-34, -10)</td>
<td class="Rrule" align="center" colspan="2">-35 (-48, -22)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mean change (%)<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">-5</td>
<td class="Rrule" align="center">16</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Mean treatment difference (95% CI)<a href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" colspan="2">-17 (-24, -10)</td>
<td class="Rrule" align="center" colspan="2">-18 (-24, -11)</td>
</tr>
</tbody>
</table>
<p>Figure 2. shows the percent change in VAT from baseline (Week 0) over time until 52 weeks in completer patients.</p>
<p><span class="Bold">Figure 2. Percent Change from Baseline in VAT over Time</span></p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-03.jpg"></div>
<p>Data in Figure 2 are expressed as mean values. T-T (tesamorelin to tesamorelin) refers to the group of patients who received tesamorelin for Weeks 0-26 and were re-randomized to tesamorelin for Weeks 26-52. T-P (tesamorelin to placebo) refers to the group of patients who received tesamorelin for Weeks 0-26 and were re-randomized to placebo for Weeks 26-52. P-T (placebo to tesamorelin) refers to the group of patients who received placebo for Weeks 0-26 and were switched to tesamorelin (treated open label) for Weeks 26-52.</p>
<a name="table6"></a><table width="100%">
<caption><span>Table 6: Changes from Week 26 Baseline to Week 52 in IGF-1, IGFBP-3, Weight, and Waist Circumference by Treatment Group (Intent-To-Treat Population with Last Observation Carried Forward)</span></caption>
<col align="center" valign="middle" width="16%">
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="6">EXTENSION PHASE (Weeks 26-52)</th></tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Study 1</th>
<th class="Rrule" align="center" colspan="2">Study 2</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center">T-T<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a><br>(Week 26-52)<br>(N=154)</th>
<th class="Rrule" align="center">T-P<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a><br>(Week 26-52)<br>(N=50)</th>
<th class="Rrule" align="center">T-T<a href="#footnote-7" class="Sup">*</a><br>(Week 26-52)<br>(N=92)</th>
<th class="Rrule" align="center">T-P<a href="#footnote-8" class="Sup">†</a><br>(Week 26-52)<br>(N=85)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="6" valign="top">Week 26 baseline data are expressed as mean (SD); Change refers to least-squares mean (LSM); CI: confidence interval.</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>T-T = tesamorelin for Week 0-26 and tesamorelin for Week 26-52</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>T-P = tesamorelin for Week 0-26 and placebo for Week 26-52</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" rowspan="3">IGF-1<br>(ng/mL)</td>
<td class="Rrule" align="left">Week 26</td>
<td class="Rrule" align="center">291 (124)</td>
<td class="Rrule" align="center">281 (105)</td>
<td class="Rrule" align="center">280 (134)</td>
<td class="Rrule" align="center">269 (110)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Change</td>
<td class="Rrule" align="center">-59</td>
<td class="Rrule" align="center">-137</td>
<td class="Rrule" align="center">-25</td>
<td class="Rrule" align="center">-135</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Mean treatment difference (95% CI)</td>
<td class="Rrule" align="center" colspan="2">78 (50, 106)</td>
<td class="Rrule" align="center" colspan="2">110 (87, 134)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" rowspan="3">IGFBP-3<br>(mg/L)</td>
<td class="Rrule" align="left">Week 26</td>
<td class="Rrule" align="center">3 (1)</td>
<td class="Rrule" align="center">3 (1)</td>
<td class="Rrule" align="center">3 (1)</td>
<td class="Rrule" align="center">3 (1)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Change</td>
<td class="Rrule" align="center">-0.2</td>
<td class="Rrule" align="center">-0.5</td>
<td class="Rrule" align="center">-0.3</td>
<td class="Rrule" align="center">-0.9</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Mean treatment difference (95% CI)</td>
<td class="Rrule" align="center" colspan="2">0.3 (-0.0, 0.6)</td>
<td class="Rrule" align="center" colspan="2">0.6 (0.3, 0.9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" rowspan="3">Weight (kg)</td>
<td class="Rrule" align="left">Week 26</td>
<td class="Rrule" align="center">89 (14)</td>
<td class="Rrule" align="center">92 (17)</td>
<td class="Rrule" align="center">89 (13)</td>
<td class="Rrule" align="center">90 (14)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Change</td>
<td class="Rrule" align="center">0.2</td>
<td class="Rrule" align="center">0.6</td>
<td class="Rrule" align="center">-0.5</td>
<td class="Rrule" align="center">0.1</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Mean treatment difference (95% CI)</td>
<td class="Rrule" align="center" colspan="2">-0.4 (-2, 1)</td>
<td class="Rrule" align="center" colspan="2">-0.6 (-2, 1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" rowspan="3">Waist circumference (cm)</td>
<td class="Rrule" align="left">Week 26</td>
<td class="Rrule" align="center">101 (10)</td>
<td class="Rrule" align="center">102 (12)</td>
<td class="Rrule" align="center">101 (9)</td>
<td class="Rrule" align="center">103 (11)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Change</td>
<td class="Rrule" align="center">-0.2</td>
<td class="Rrule" align="center">2.4</td>
<td class="Rrule" align="center">-1.1</td>
<td class="Rrule" align="center">0.2</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">Mean treatment difference (95% CI)</td>
<td class="Rrule" align="center" colspan="2">-2.6 (-4, -1)</td>
<td class="Rrule" align="center" colspan="2">-1.3 (-2, 0)</td>
</tr>
</tbody>
</table>
<p>Patients treated with EGRIFTA<span class="Italics">®</span> for 52 weeks (T-T group) showed no change between Weeks 26 and 52 in mean trunk fat (increase of 0.1 kg in Study 1 and decrease of 0.5 kg in Study 2, respectively, compared with an increase of 1.4 kg in patients in the T-P group in Study 1 and an increase of 1.09 kg in Study 2, respectively) nor was there a change from Week 26 baseline in mean lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> (decrease of 0.1 kg in Study 1 and increase of 0.1 kg in Study 2, respectively, compared with a decrease of 1.8 kg in patients in the T-P group in Study 1 and a decrease of 1.7 kg in Study 2, respectively).</p>
<p>There was no adverse effect of EGRIFTA<span class="Sup">® </span>on lipids or subcutaneous adipose tissue (SAT). EGRIFTA<span class="Italics">®</span> did not adversely alter antiretroviral effectiveness, such as mean circulating levels of CD4 counts or HIV-1 RNA (viral load).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">EGRIFTA<span class="Italics">®</span> (tesamorelin for injection) is supplied as a sterile, white to off-white lyophilized powder. Each single-use vial of EGRIFTA<span class="Italics">®</span> contains 2 mg of tesamorelin as the free base (2.2 mg tesamorelin acetate, anhydrous) and the following inactive ingredient: 100 mg mannitol, USP.</p>
<p>EGRIFTA<span class="Italics">®</span> is available in a package comprised of two boxes. One box contains 30 vials of EGRIFTA<span class="Italics">®</span> and a second box contains 30 single-use 10 mL bottles of reconstitution diluent (Sterile Water for Injection, USP), disposable syringes, and needles sufficient for a 30 day supply.</p>
<p>After reconstitution with Sterile Water for Injection, USP the reconstituted solution concentration is 1 mg/mL and should be injected immediately.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">EGRIFTA<span class="Italics">®</span> vials should be protected from light and be kept in the original box until time of use. Non-reconstituted EGRIFTA<span class="Italics">®</span> must be stored at refrigerated temperature, between 2°C and 8°C (36°F and 46°F) until dispensed. Upon dispensing, the patient may store non-reconstituted EGRIFTA<span class="Italics">®</span> at refrigerated temperature until the expiration date, or at or below 25°C (77°F) for 3 months or until the expiration date, whichever occurs first. The reconstitution diluent (Sterile Water for Injection, USP), syringes and needles should be stored at controlled room temperature of 20ºC to 25ºC (68°F to 77°F).</p>
<p>Syringes and needles are for single-use by a single patient and should never be shared between patients.</p>
<p>NDC 44087-2011-2</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (<a href="#pi">Patient Information</a> and <a href="#pifu">Patient Instructions for Use</a>).</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> (<a href="#s5.3">5.3</a>) – Advise patients that treatment with EGRIFTA<span class="Italics">®</span> may cause symptoms consistent with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, including <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span>. These reactions are either transient or resolve with discontinuation of treatment.</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> (<a href="#s5.5">5.5</a>) – Advise patients that <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>) may occur during treatment with EGRIFTA<span class="Italics">®</span>. Advise patients to seek prompt medical attention and to immediately discontinue treatment with EGRIFTA<span class="Italics">®</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reactions</span> (<a href="#s5.6">5.6</a>) – Advise patients   of possible <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>, including injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>,   <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, irritation, and <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>. To reduce the incidence of   <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>, advise patients to rotate the site of injection.</li>
<li>Counsel patients that they should never share an EGRIFTA<span class="Italics">®</span>   syringe with another person, even if the needle is changed. Sharing of   syringes or needles between patients may pose a risk of transmission of   <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
</ul>
<div class="Section" data-sectionCode="42228-7">
<a name="section-15.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy</span></p>
<p>Advise women to discontinue EGRIFTA<span class="Italics">®</span> if pregnancy occurs, as the drug offers no known benefit to pregnant women and could result in fetal harm <span class="Italics">[see <a href="#s4.4">Contraindications (4.4)</a> and <a href="#S8.1">Use in Specific Populations (8.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-15.2"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers</span></p>
<p>Because of both the potential for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> transmission and serious adverse reactions in nursing infants, mothers receiving EGRIFTA<span class="Italics">®</span> should be instructed not to human milk-feed <span class="Italics">[see <a href="#S8.3">Use in Specific Populations (8.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First"><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-04.jpg"></p>
<p>EGRIFTA<span class="Sup">®</span> is a registered trademark of Theratechnologies Inc.</p>
<p>Distributed by: EMD Serono, Inc., Rockland, MA 02370, USA</p>
<p>Date:  01/2013</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="pi"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">EGRIFTA<span class="Sup">®</span></span> (eh-GRIF-tuh)</p>
<p><span class="Italics">(tesamorelin for injection) for subcutaneous use</span></p>
<p><span class="Bold">Read the Patient Information that comes with EGRIFTA<span class="Italics">®</span></span> before you start to take it and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">What is EGRIFTA®?</span></p>
<ul class="Disc">
<li>EGRIFTA<span class="Bold">®</span> is an injectable prescription medicine to reduce the excess in abdominal fat in HIV-infected patients with <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>. EGRIFTA® contains a growth hormone-releasing factor (GRF).</li>
<li>The impact and safety of EGRIFTA® on cardiovascular health has not been studied.</li>
<li>EGRIFTA® is not indicated for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> management.</li>
<li>It is not known whether taking EGRIFTA® helps improve compliance with anti-retroviral medications.</li>
<li>It is not known if EGRIFTA® is safe and effective in children. EGRIFTA® is not recommended to be used in children.</li>
</ul>
<p><span class="Bold">Who should not use EGRIFTA®?</span></p>
<p>Do not use EGRIFTA® if you:</p>
<ul class="Disc">
<li>have pituitary gland tumor, pituitary gland surgery or other problems related to your pituitary gland</li>
<li>have active cancer (either newly diagnosed or recurrent) or are receiving treatment for cancer.</li>
<li>are allergic to tesamorelin or any of the ingredients in EGRIFTA®. See the end of this leaflet for a complete list of ingredients in EGRIFTA®</li>
<li>are pregnant or become pregnant. If you become pregnant, stop using EGRIFTA® and talk with your healthcare provider. See <a href="#tell">"What should I tell my healthcare provider before using EGRIFTA®?"</a>
</li>
</ul>
<p><a name="tell"></a><span class="Bold">What should I tell my healthcare provider before using EGRIFTA®?</span></p>
<p>Before using EGRIFTA®, tell your healthcare provider if you:</p>
<ul class="Disc">
<li>have or have had cancer</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>are breastfeeding or plan to breastfeed. It is not known if EGRIFTA® passes into your breast milk. The Centers for Disease Control and Prevention (CDC) recommends that HIV-infected mothers not breastfeed to avoid the risk of passing <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> to your baby. Talk with your healthcare provider about the best way to feed your baby if you are taking EGRIFTA®</li>
<li>have kidney or liver problems</li>
<li>have any other medical condition.</li>
</ul>
<p>Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. EGRIFTA® may affect the way other medicines work, and other medicines may affect how EGRIFTA® works.</p>
<p>Know the medicines you take. Keep a list with you to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I use EGRIFTA®?</span></p>
<ul class="Disc">
<li>
<span class="Bold">Read the detailed "Instructions for Use"</span> that comes with EGRIFTA® before you start using EGRIFTA®. Your healthcare provider will show you how to inject EGRIFTA®.</li>
<li>Use EGRIFTA® exactly as prescribed by your healthcare provider.</li>
<li>Inject EGRIFTA® under the skin (subcutaneously) of your stomach area (abdomen).</li>
<li>Change (rotate) the injection site on your stomach area (abdomen) with each dose. Do not inject EGRIFTA® into <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scar</span> tissue, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruises</span> or your navel.</li>
<li>
<span class="Bold">Do not</span> share needles or syringes with other people. Sharing of needles can result in the transmission of infectious diseases, such as HIV.</li>
</ul>
<p><span class="Bold">What are the possible side effects of EGRIFTA®?</span></p>
<p><span class="Bold">EGRIFTA® may cause serious side effects including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. </span>Some people taking EGRIFTA<span class="Italics">®</span> may have an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.<p class="First"><span class="Bold">Stop using EGRIFTA<span class="Italics">®</span> and get emergency help right away if you have any of the following symptoms:</span></p>
<table class="Noautorules" width="60%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Disc">
<li>a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> over your body</li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face or throat</li>
</ul></td>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing</li>
<li>fast heartbeat</li>
<li>feeling of faintness or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
</ul></td>
</tr></tbody>
</table>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>). </span>EGRIFTA® can cause <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in some parts of your body. Call your healthcare provider if you have an increase in <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in your hands or wrist (<span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span>).</li>
<li>
<span class="Bold">Increase in glucose (blood sugar) intolerance and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</span> Your healthcare provider will measure your blood sugar periodically.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span>. </span>Change (rotate) your injection site to help lower your risk for <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>. Call your healthcare provider for medical advice if you have the following symptoms around the area of the injection site:<table class="Noautorules" width="60%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>irritation</li>
</ul></td>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
</ul></td>
</tr></tbody>
</table>
</li>
</ul>
<p><span class="Bold">The most common side effects of EGRIFTA® include</span>:</p>
<table class="Noautorules" width="60%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in legs</span> and arms</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your legs</li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle soreness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> and pricking</li>
</ul></td>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
</ul></td>
</tr></tbody>
</table>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of EGRIFTA®. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. To report side effects, contact EMD Serono toll-free at 1-800-283-8088 ext. 5563. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How do I store EGRIFTA®?</span></p>
<ul class="Disc">
<li>EGRIFTA® has two boxes dispensed by the pharmacy<ul class="Disc">
<li>Store the Medication Box of EGRIFTA® vials in the refrigerator between 2°C and 8°C (36°F and 46°F) until the expiration date, or at or below 25°C (77°F) for 3 months or until the expiration date, whichever occurs first.</li>
<li>Store the box of Sterile Water for Injection, syringes and needles at room temperature between 20ºC to 25ºC (68°F to 77°F).</li>
</ul>
</li>
<li>Keep EGRIFTA<span class="Italics">®</span> vials in Medication Box away from light.</li>
<li>Do not freeze.</li>
<li>Do not use EGRIFTA<span class="Italics">®</span> after the expiration date printed on the carton and vial labels.</li>
<li>After mixing, use EGRIFTA<span class="Italics">®</span> right away and throw away any unused EGRIFTA<span class="Italics">®</span>. Do not store mixed EGRIFTA<span class="Italics">®</span>. Also, throw away the used bottle of Sterile Water for Injection.</li>
</ul>
<p><span class="Bold">Keep EGRIFTA® and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of EGRIFTA<span class="Italics">®</span></span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use EGRIFTA<span class="Italics">®</span> for a condition for which it was not prescribed. Do not give EGRIFTA<span class="Italics">®</span> to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>Do not share your EGRIFTA<span class="Italics">®</span> syringe with another person, even if the needle is changed. Do not share your EGRIFTA<span class="Italics">®</span> needles with another person.</p>
<p>This Patient Information leaflet summarizes the most important information about EGRIFTA<span class="Italics">®</span>. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about EGRIFTA<span class="Italics">®</span> that is written for healthcare professionals.</p>
<p>For more information about EGRIFTA<span class="Italics">®</span>, go to www.EGRIFTA.com or contact the AXIS Center toll-free at 1-877-714-2947.</p>
<p><span class="Bold">What are the ingredients in EGRIFTA<span class="Italics">®</span>?</span></p>
<p><span class="Bold">Active ingredient</span>: tesamorelin </p>
<p><span class="Bold">Inactive ingredients:</span> mannitol and Sterile Water for Injection</p>
<p><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-04.jpg"></p>
<p>EGRIFTA<span class="Italics"><span class="Sup">®</span></span> is a registered trademark of Theratechnologies Inc.</p>
<p>Distributed by: EMD Serono, Inc., Rockland, MA 02370, USA</p>
<p>Date: 01/2013</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="pifu"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Patient Instructions for Use</span></p>
<p><span class="Bold">EGRIFTA</span><span class="Sup">®</span> (eh-GRIF-tuh)</p>
<p><span class="Italics">(tesamorelin for injection) for subcutaneous use</span></p>
<p>Be sure that you read, understand, and follow these Patient Instructions for Use before using EGRIFTA®. Your healthcare provider should show you how to mix and inject EGRIFTA® before you inject it for the first time. Ask your healthcare provider if you have any questions.</p>
<p>Keep this leaflet in case you need to look at it again later.</p>
<p><span class="Bold">Important information for use of EGRIFTA</span><span class="Sup">®</span></p>
<ul class="Disc">
<li>After mixing EGRIFTA® with Sterile Water   for Injection, it should look clear and colorless, with no particles in   it. Do not use EGRIFTA® if it looks cloudy, discolored, or if you see   particles in it. Talk to your healthcare provider if you have any   questions.</li>
<li>Do not use EGRIFTA® after the date on   the Medication Box and EGRIFTA® vial.</li>
<li>Do not use a syringe or needle more   than 1 time.</li>
<li>Do not share your EGRIFTA® needles with another person. Sharing of needles can result in the transmission of infectious diseases, such as HIV. Do not share your EGRIFTA® syringe with another person, even if the needle is changed.</li>
<li>If you are missing any supplies from   your Medication Box or Injection Box, or if anything looks damaged call   your pharmacist or contact the AXIS Center toll-free at 1-877-714-2947   right away.</li>
</ul>
<p><span class="Bold">Preparing for your EGRIFTA</span><span class="Sup">®</span><span class="Bold"> injection</span></p>
<p>Step 1:   Find a well-lit, clean, and flat surface, such as a table.</p>
<p>Step 2:   Gather your supplies:</p>
<ul class="Disc">
<li>Medication Box that contains 30 EGRIFTA® powder vials</li>
<li>Injection Box that contains the following:<dl>
<dt>a)</dt>
<dd>30 10-mL bottles of Sterile Water for Injection, used for mixing</dd>
<dt>b)</dt>
<dd>30 sterile 3-mL syringes with sterile needle already attached (BD 3 mL Syringe)</dd>
<dt>c)</dt>
<dd>30 individual ½" 27-gauge injection needles (BD Eclipse™ Injection Needle)</dd>
</dl>
</li>
<li>Other Supplies Needed<ul class="Disc">
<li>Alcohol pads</li>
<li>Sterile gauze</li>
<li>A "sharps container" or a puncture resistant container for throwing away needles after you are done with them. The container should be made from hard plastic or metal. Make sure it has a lid. You can also put used syringes or empty vials of medicine in the container.</li>
</ul>
</li>
</ul>
<p><span class="Bold">Material included in Injection Box (a, b, c) and Medication Box (d):</span></p>
<p><a name="figa"></a><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-05.jpg"></p>
<p>Step 3:	Take out the following from your Injection Box:</p>
<ul class="Disc">
<li>A Sterile Water for Injection bottle (Figure A, a)</li>
<li>A syringe with needle already attached (Figure A, b)</li>
<li>A ½" 27-gauge injection needle with pink needle shield (Figure A, c)</li>
</ul>
<p>Step 4:	Take one EGRIFTA® vial (Figure A, d) from the Medication Box. Put the box with the remaining vials back in the refrigerator right away.</p>
<p>Step 5:	Prepare to use your supplies:</p>
<ul class="Disc">
<li>Wash your hands with soap and water. Dry your hands with a clean towel.</li>
<li>Take off the plastic caps from the vials of EGRIFTA® and Sterile Water bottle.</li>
<li>Clean the rubber stopper on top of the vial of EGRIFTA® and Sterile Water bottle with an alcohol swab.</li>
</ul>
<p><span class="Bold">How to mix EGRIFTA<span class="Sup">®</span></span></p>
<p><span class="Underline">Step 1</span>: Pick up the syringe with needle attached (Figure A, b), remove the protective cap and insert the needle through the rubber stopper of the bottle of Sterile Water (Figure A, a; see <a href="#figbc">Figure B</a> for illustration). Turn both upside down, and pull back the plunger until the liquid reaches the 2.1 mL mark on the syringe. (See <a href="#figbc">Figure C</a>)</p>
<a name="figbc"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-06.jpg"></td>
<td align="left"><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-07.jpg"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure B</span></td>
<td align="left"><span class="Underline">Figure C</span></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Step 2</span>: Take the syringe with needle attached out of the Sterile Water bottle and insert the needle into the EGRIFTA® vial. Push the plunger in slowly on a slight angle so water goes down the inside wall of the EGRIFTA® vial instead of directly onto the powder to avoid foaming. (See <a href="#figd">Figure D</a>)</p>
<a name="figd"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-08.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure D</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Step 3</span>: While keeping the syringe with needle attached in the vial and the vial upright, roll the vial gently in your hands for 30 seconds, until the Sterile Water and EGRIFTA® powder are mixed well. Do <span class="Bold">not</span> shake the vial. (See <a href="#fige">Figure E</a>)</p>
<a name="fige"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-09.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure E</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Step 4</span>: Still keeping the syringe with needle attached in the vial, turn both until the syringe is straight up. Pull down on the syringe until you see just the tip of the needle going through the rubber stopper, then pull back on the plunger until all the liquid inside the vial goes into the syringe. The level of medicine in the syringe should be around the 2.1 mL syringe mark. (See <a href="#figf">Figure F</a>)</p>
<a name="figf"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-10.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure F</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Step 5</span>: Take the needle out of the vial. (See <a href="#figg">Figure G</a>)</p>
<a name="figg"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-11.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure G</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Step 6</span>: Place the needle cap on its side against a clean flat surface. Without touching the needle, hold the syringe and slide the needle carefully into the protective cap (See <a href="#figh">Figure H</a>). Push the cap all the way or until it snaps shut (See <a href="#figi">Figure I</a>). Do not touch the cap until it covers the needle completely.</p>
<a name="figh"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure H" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-12.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure H</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<a name="figi"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure I" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-13.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure I</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Step 7</span>: With the cap on the needle, remove the needle by holding the syringe firmly and twisting the cap counterclockwise (to the left). (See <a href="#figj">Figure J</a>)</p>
<a name="figj"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure J" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-14.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure J</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Step 8</span>: Place the injection needle (Figure A, c), with its white protective cap in place, onto the syringe. Hold the syringe firmly and twist the cap clockwise (to the right) until it closes securely. (See <a href="#figk">Figure K</a>)</p>
<a name="figk"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure K" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-15.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure K</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Where do I inject EGRIFTA</span><span class="Sup">®</span><span class="Bold">?</span></p>
<p>You should inject EGRIFTA® into the skin on your stomach (abdomen). (See <a href="#figl">Figure L</a>)</p>
<ul class="Disc">
<li>Pick an injection site that is around your belly button to the left or right.</li>
<li>Stay away from any area with <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scar</span> tissue, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruises</span>, reddening, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or irritation.</li>
<li>Avoid areas with any hard bumps from previous injections.</li>
<li>Change your injection site from one day to the next. This may help prevent <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or irritation. You may want to keep a note of the date and location of each daily injection to help you remember.</li>
</ul>
<a name="figl"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure L" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-16.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure L</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p><span class="Bold">How to inject EGRIFTA</span>®</p>
<ul class="Disc"><li>Pick up the syringe and pull the cap straight off the injection needle. Do <span class="Bold">not</span> twist it. (See <a href="#figm">Figure M</a>)</li></ul>
<a name="figm"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure M" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-17.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure M</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<ul class="Disc"><li>Tap the syringe gently with your finger to force any air bubbles to rise to the top. Press the plunger to push bubbles out. (See <a href="#fign">Figure N</a>)</li></ul>
<a name="fign"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure N" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-18.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure N</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<ul class="Disc"><li>Clean the injection site you have selected with an alcohol swab and let it dry. Hold the syringe in one hand. Use your other hand to hold a cleaned fold of skin for your injection. Hold the skin between your thumb and fingers. (See <a href="#figo">Figure O</a>)</li></ul>
<a name="figo"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure O" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-19.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure O</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<ul class="Disc"><li>Hold the syringe at a right angle to the skin, like a dart. Push the injection needle into the skin with a quick motion. Most of the needle should go beneath the skin surface. (See <a href="#figp">Figure P</a>)</li></ul>
<a name="figp"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure P" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-20.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure P</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<ul class="Disc"><li>Remove your hand from the pinched area of skin after the needle goes in. Make sure the needle stays in the skin. (See <a href="#figq">Figure Q</a>)</li></ul>
<a name="figq"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure Q" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-21.jpg"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Figure Q</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<ul class="Disc">
<li>Slowly push the plunger all the way down until all of the medicine in the syringe has been injected under the skin.</li>
<li>Pull the injection needle out of your skin when the syringe is empty:<ul class="Disc">
<li>Be careful to pull it out at the same angle you put it in</li>
<li>Flip back the pink needle shield until it snaps, covering the injection needle completely. Keep pressing until you hear a click, that means the injection needle is protected. (See <a href="#figr">Figure R</a>)</li>
</ul>
</li>
</ul>
<a name="figr"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><span class="Underline">Figure R</span></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><img alt="Figure R" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-22.jpg"></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<ul class="Disc"><li>Use a piece of sterile gauze to rub the injection site clean. If there is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, apply pressure to the injection site with gauze for 30 seconds. If <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> continues, apply a bandage to the site.</li></ul>
<p><span class="Bold">How should I dispose of the used syringes, needles, bottles and vials?</span></p>
<ul class="Disc">
<li><span class="Italics">If you accidentally prick another person with a used needle, that person should be informed to contact a healthcare provider right away about the <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>.</span></li>
<li>Never reuse or recycle needles or syringes.</li>
<li>Never throw used needles, syringes, or the sharps container into the trash.</li>
<li>Throw away used syringes, needles, EGRIFTA® vials and Sterile Water for Injection bottle in a puncture-proof container, sharps container, or a hard container like a coffee can.</li>
<li>Speak to your pharmacist or other healthcare provider about the proper disposal of the sharps container and all other used materials. There may be local or state laws about how to throw away used needles and syringes.</li>
<li>Keep the sharps container away from children and pets.</li>
</ul>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="100%">
<tbody class="Headless"><tr><td class="Botrule Lrule Rrule Toprule" align="left">
<span class="Bold">If you have any questions,</span> call your healthcare provider. You can call the AXIS Center toll-free at 1-877-714-2947 or visit the EGRIFTA® Web site at: www.EGRIFTA.com for more information.</td></tr></tbody>
</table>
<p><span class="Bold">How do I store EGRIFTA</span><span class="Sup">®</span><span class="Bold">?</span></p>
<ul class="Disc">
<li>EGRIFTA® has two boxes dispensed by the pharmacy<ul class="Disc">
<li>Store the Medication Box of EGRIFTA® vials in the refrigerator between 2°C and 8°C (36°F and 46°F) until the expiration date, or at or below 25°C (77°F) for 3 months or until the expiration date, whichever occurs first.</li>
<li>Store the Injection Box of Sterile Water for Injection, syringes and needles at room temperature between 20ºC to 25ºC (68°F to 77°F).</li>
</ul>
</li>
<li>Keep EGRIFTA® vials away from light.</li>
<li>Do not freeze.</li>
<li>After mixing, use EGRIFTA<span class="Bold Italics">®</span> right away and throw away any unused EGRIFTA<span class="Bold Italics">®</span>. Do not store mixed EGRIFTA<span class="Bold Italics">®</span>. Also, throw away the used bottle of Sterile Water for Injection. </li>
<li>Do not use EGRIFTA® after the expiration date printed on the Medication Box and vial labels.</li>
</ul>
<p><span class="Bold">Keep EGRIFTA</span><span class="Sup">®</span><span class="Bold"> and all medicines out of the reach of children.</span></p>
<p><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-04.jpg"></p>
<p>EGRIFTA<span class="Sup">®</span> is a registered trademark of Theratechnologies Inc.</p>
<p>Distributed by: EMD Serono, Inc., Rockland, MA 02370, USA</p>
<p>Date: 01/2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL PRINCIPAL DISPLAY PANEL</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-23.jpg"></div>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-24.jpg"></div>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3de31cec-31dc-4ac4-9717-367a687d22f2&amp;name=egrifta-25.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EGRIFTA 		
					</strong><br><span class="contentTableReg">tesamorelin kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:44087-2011</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44087-2011-2</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">30 VIAL </td>
<td class="formItem">60 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">30 BOTTLE </td>
<td class="formItem">300 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>EGRIFTA 		
					</strong><br><span class="contentTableReg">tesamorelin injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TESAMORELIN ACETATE</strong> (TESAMORELIN) </td>
<td class="formItem">TESAMORELIN</td>
<td class="formItem">2 mg  in 2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">100 mg  in 2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white ) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022505</td>
<td class="formItem">09/05/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">sterile water injection</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-4887</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-4887-34</td>
<td class="formItem">10 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018801</td>
<td class="formItem">09/05/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022505</td>
<td class="formItem">09/05/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>EMD Serono, Inc.
							(088514898)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>EMD Serono, Inc. (088514898)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9952905b-10a4-45d6-8eec-c4104aca002f</div>
<div>Set id: 3de31cec-31dc-4ac4-9717-367a687d22f2</div>
<div>Version: 4</div>
<div>Effective Time: 20130221</div>
</div>
</div> <div class="DistributorName">EMD Serono, Inc.</div></p>
</body></html>
